Breaking News Instant updates and real-time market news.

DRE

Duke Realty

$55.49 /

-0.155 (-0.28%)

16:23
10/27/21
10/27
16:23
10/27/21
16:23

Duke Realty reports Q3 core FFO EPS 46c, consensus 44c

Reports Q3 revenue $280.37M, two estimates $256.72M. "I am pleased to announce our third quarter operating results, which were highlighted by record cash rent growth and substantially elevated leasing volumes across our portfolio," said Jim Connor, chairman and CEO. "We leased 9.5 million square feet during the quarter, an increase of 25 percent over the second quarter, of which 3.1 million square feet was speculative space in our development pipeline. Rent growth on second generation leasing was 34.8 percent growth in net effective rents and 21.9 percent growth on a cash basis. This quarter's rent growth is even more impressive when considering that second generation rent growth was only 25 percent in coastal Tier 1 markets compared to approximately 40 percent of our portfolio being concentrated in such markets."

  • 28

    Oct

  • 09

    Nov

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks
Soleno to submit study proposal to FDA for DCCR following Type C meeting » 08:06
01/24/22
01/24
08:06
01/24/22
08:06
SLNO

Soleno Therapeutics

/

+

Soleno Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SLNO Soleno Therapeutics
/

+

SLNO Soleno Therapeutics
/

+

Hot Stocks
SWM, ConvaTec enter long-term supply agreement » 08:06
01/24/22
01/24
08:06
01/24/22
08:06
SWM

Schweitzer-Mauduit

$29.55 /

-0.43 (-1.43%)

, CNVVY

ConvaTec

$9.68 /

-0.01 (-0.10%)

Schweitzer-Mauduit…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SWM Schweitzer-Mauduit
$29.55 /

-0.43 (-1.43%)

SWM Schweitzer-Mauduit
$29.55 /

-0.43 (-1.43%)

CNVVY ConvaTec
$9.68 /

-0.01 (-0.10%)

01/21/22 JPMorgan
ConvaTec price target lowered to 256 GBp from 278 GBp at JPMorgan
11/24/21 RBC Capital
ConvaTec price target lowered to 195 GBp from 213 GBp at RBC Capital
11/02/21 UBS
ConvaTec price target lowered to 250 GBp from 252 GBp at UBS
11/01/21 Barclays
ConvaTec price target raised to 290 GBp from 275 GBp at Barclays
Hot Stocks
Amyris to acquire Menolabs for menopause symptoms » 08:05
01/24/22
01/24
08:05
01/24/22
08:05
AMRS

Amyris

$4.17 /

-0.315 (-7.02%)

Amyris has agreed to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMRS Amyris
$4.17 /

-0.315 (-7.02%)

AMRS Amyris
$4.17 /

-0.315 (-7.02%)

11/09/21 Roth Capital
Amyris price target lowered to $15 from $22 at Roth Capital
10/14/21 Cowen
Amyris coverage transferred at Cowen
08/06/21 H.C. Wainwright
Amyris price target lowered to $30 from $35 at H.C. Wainwright
07/06/21 HSBC
Amyris is at 'tipping point on growth,' says HSBC
AMRS Amyris
$4.17 /

-0.315 (-7.02%)

  • 09
    Apr
AMRS Amyris
$4.17 /

-0.315 (-7.02%)

AMRS Amyris
$4.17 /

-0.315 (-7.02%)

AMRS Amyris
$4.17 /

-0.315 (-7.02%)

Earnings
Sierra Bancorp reports Q4 EPS 63c, consensus 66c » 08:05
01/24/22
01/24
08:05
01/24/22
08:05
BSRR

Sierra Bancorp

$27.74 /

+0.41 (+1.50%)

Reports Q4 tangible book…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BSRR Sierra Bancorp
$27.74 /

+0.41 (+1.50%)

BSRR Sierra Bancorp
$27.74 /

+0.41 (+1.50%)

12/21/21 Keefe Bruyette
Keefe Bruyette assumes four California small- and mid-cap banks
12/20/21 Keefe Bruyette
Sierra Bancorp assumed with an Outperform at Keefe Bruyette
Recommendations
Vor Biopharma price target lowered to $46 from $60 at B. Riley » 08:05
01/24/22
01/24
08:05
01/24/22
08:05
VOR

Vor Biopharma

/

+

B. Riley analyst Justin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VOR Vor Biopharma
/

+

VOR Vor Biopharma
/

+

12/17/21 H.C. Wainwright
Vor Biopharma initiated with a Buy at H.C. Wainwright
12/03/21 Baird
Baird start Vor Biopharma with an Outperform ahead of AML data
12/02/21 Baird
Vor Biopharma initiated with an Outperform at Baird
12/01/21 Oppenheimer
Vor Biopharma initiated with an Outperform at Oppenheimer
VOR Vor Biopharma
/

+

  • 05
    Feb
Recommendations
Tiziana Life Sciences price target lowered to $3 from $8 at B. Riley » 08:05
01/24/22
01/24
08:05
01/24/22
08:05
TLSA

Tiziana Life Sciences

/

+

B. Riley analyst Kalpit…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TLSA Tiziana Life Sciences
/

+

Hot Stocks
AudioCodes names Dmitry Netis as Chief Strategy Officer » 08:04
01/24/22
01/24
08:04
01/24/22
08:04
AUDC

AudioCodes

$29.24 /

-1.23 (-4.04%)

AudioCodes announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AUDC AudioCodes
$29.24 /

-1.23 (-4.04%)

AUDC AudioCodes
$29.24 /

-1.23 (-4.04%)

06:25 Today Barclays
AudioCodes price target lowered to $28 from $32 at Barclays
10/26/21 Jefferies
AudioCodes price target lowered to $36 from $38 at Jefferies
10/22/21 Sidoti
AudioCodes downgraded to Neutral from Buy at Sidoti
10/21/21 Jefferies
AudioCodes downgraded to Hold from Buy at Jefferies
AUDC AudioCodes
$29.24 /

-1.23 (-4.04%)

Recommendations
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley » 08:04
01/24/22
01/24
08:04
01/24/22
08:04
SEEL

Seelos Therapeutics

$1.18 /

-0.075 (-5.98%)

B. Riley analyst Mayank…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$1.18 /

-0.075 (-5.98%)

SEEL Seelos Therapeutics
$1.18 /

-0.075 (-5.98%)

11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
10/21/21 B. Riley
Seelos shares offer 'significant potential upside optionality,' says B. Riley
09/27/21 Roth Capital
Seelos Therapeutics upgraded to Buy from Neutral at Roth Capital
08/18/21 B. Riley
Seelos Therapeutics price target lowered to $11 from $15 at B. Riley
  • 20
    May
  • 20
    Apr
  • 26
    Jan
SEEL Seelos Therapeutics
$1.18 /

-0.075 (-5.98%)

Recommendations
Cassava Sciences price target lowered to $72 from $108 at B. Riley » 08:04
01/24/22
01/24
08:04
01/24/22
08:04
SAVA

Cassava Sciences

$36.28 /

-1.12 (-2.99%)

B. Riley analyst Mayank…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SAVA Cassava Sciences
$36.28 /

-1.12 (-2.99%)

SAVA Cassava Sciences
$36.28 /

-1.12 (-2.99%)

12/22/21 B. Riley
Cassava risk/reward improving with manipulation not found, says B. Riley
11/04/21 H.C. Wainwright
H.C. Wainwright reiterates Cassava as a 2021 top pick after Journal's review
09/23/21 B. Riley
Cassava Sciences data 'reinvigorate' investor confidence, says B. Riley
08/30/21 Cantor Fitzgerald
Cantor suspends rating on Cassava Sciences after allegations about simufilam
SAVA Cassava Sciences
$36.28 /

-1.12 (-2.99%)

SAVA Cassava Sciences
$36.28 /

-1.12 (-2.99%)

SAVA Cassava Sciences
$36.28 /

-1.12 (-2.99%)

SAVA Cassava Sciences
$36.28 /

-1.12 (-2.99%)

Recommendations
Trian involvement at Unilever likely 'materially positive,' says Jefferies » 08:04
01/24/22
01/24
08:04
01/24/22
08:04
UL

Unilever

$49.30 /

-0.125 (-0.25%)

After Financial Times…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
UL Unilever
$49.30 /

-0.125 (-0.25%)

UL Unilever
$49.30 /

-0.125 (-0.25%)

01/19/22 Societe Generale
Societe Generale double upgrades Unilever after selloff on 'clumsy' bid
01/19/22 Societe Generale
Unilever upgraded to Buy from Sell at Societe Generale
01/17/22 Bernstein
Unilever downgraded to Underperform from Market Perform at Bernstein
01/17/22 Barclays
Unilever downgraded to Equal Weight from Overweight at Barclays
UL Unilever
$49.30 /

-0.125 (-0.25%)

UL Unilever
$49.30 /

-0.125 (-0.25%)

UL Unilever
$49.30 /

-0.125 (-0.25%)

Recommendations
MediciNova price target lowered to $6 from $11 at B. Riley » 08:04
01/24/22
01/24
08:04
01/24/22
08:04
MNOV

MediciNova

$2.24 /

-0.12 (-5.08%)

B. Riley analyst Kalpit…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MNOV MediciNova
$2.24 /

-0.12 (-5.08%)

MNOV MediciNova
$2.24 /

-0.12 (-5.08%)

03/10/21
Fly Intel: Top five analyst initiations
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
MNOV MediciNova
$2.24 /

-0.12 (-5.08%)

Hot Stocks
Codexis announces FDA ODD for CDX-6512 » 08:04
01/24/22
01/24
08:04
01/24/22
08:04
CDXS

Codexis

$19.86 /

-0.92 (-4.43%)

Codexis announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CDXS Codexis
$19.86 /

-0.92 (-4.43%)

CDXS Codexis
$19.86 /

-0.92 (-4.43%)

12/31/21 Benchmark
Pfizer COVID-19 pill approval in UK could be boost for Codexis, says Benchmark
12/22/21 Craig-Hallum
Craig-Hallum bullish on Codexis, sees potential for upside to 2022 estimates
11/18/21 Benchmark
Pfizer's antiviral pill deal raises Benchmark's confidence in Codexis estimates
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
CDXS Codexis
$19.86 /

-0.92 (-4.43%)

CDXS Codexis
$19.86 /

-0.92 (-4.43%)

Hot Stocks
Apollo Global, Athene, BNP Paribas partner to launch Eliant Inventory Solutions » 08:03
01/24/22
01/24
08:03
01/24/22
08:03
APO

Apollo Global

$66.00 /

-1 (-1.49%)

, BNPQY

BNP Paribas

$35.07 /

-0.91 (-2.53%)

Apollo (APO) and its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
APO Apollo Global
$66.00 /

-1 (-1.49%)

BNPQY BNP Paribas
$35.07 /

-0.91 (-2.53%)

APO Apollo Global
$66.00 /

-1 (-1.49%)

01/13/22 Deutsche Bank
Apollo Global price target lowered to $101 from $110 at Deutsche Bank
01/03/22 Keefe Bruyette
Apollo long, Rocket short amid KBW's 13 best ideas for 2022
12/17/21 Deutsche Bank
Apollo Global price target raised to $110 from $91 at Deutsche Bank
12/16/21 BofA
Apollo Global reinstated with an Underperform at BofA
BNPQY BNP Paribas
$35.07 /

-0.91 (-2.53%)

01/20/22 Deutsche Bank
BNP Paribas price target raised to EUR 75 from EUR 66 at Deutsche Bank
01/19/22 DZ Bank
BNP Paribas upgraded to Buy from Hold at DZ Bank
01/06/22 JPMorgan
BNP Paribas price target raised to EUR 69 from EUR 63 at JPMorgan
12/21/21 Kepler Cheuvreux
BNP Paribas upgraded to Buy from Hold at Kepler Cheuvreux
APO Apollo Global
$66.00 /

-1 (-1.49%)

APO Apollo Global
$66.00 /

-1 (-1.49%)

BNPQY BNP Paribas
$35.07 /

-0.91 (-2.53%)

APO Apollo Global
$66.00 /

-1 (-1.49%)

BNPQY BNP Paribas
$35.07 /

-0.91 (-2.53%)

APO Apollo Global
$66.00 /

-1 (-1.49%)

Downgrade
Opko Health downgraded to Market Perform from Outperform at Barrington » 08:03
01/24/22
01/24
08:03
01/24/22
08:03
OPK

Opko Health

/

+

Barrington analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OPK Opko Health
/

+

OPK Opko Health
/

+

01/20/22 Piper Sandler
Piper reiterates $6 target on Opko after Japan approval, awaits FDA
01/18/22 Piper Sandler
Opko Health price target raised to $6 from $5 at Piper Sandler
09/27/21 Barrington
Barrington says Somatrogon delay does not change Opko Health view
09/24/21 Piper Sandler
Piper confident in Opko's somatrogon approval despite BLA review delay
OPK Opko Health
/

+

OPK Opko Health
/

+

Recommendations
Magenta Therapeutics price target lowered to $6 from $13 at B. Riley » 08:03
01/24/22
01/24
08:03
01/24/22
08:03
MGTA

Magenta Therapeutics

$3.58 /

-0.125 (-3.37%)

B. Riley analyst Kalpit…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MGTA Magenta Therapeutics
$3.58 /

-0.125 (-3.37%)

MGTA Magenta Therapeutics
$3.58 /

-0.125 (-3.37%)

01/05/22 Goldman Sachs
Magenta Therapeutics upgraded to Buy from Neutral at Goldman Sachs
08/19/21 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
08/03/21
Fly Intel: Top five analyst downgrades
08/03/21 JPMorgan
Magenta Therapeutics downgraded to Neutral from Overweight at JPMorgan
MGTA Magenta Therapeutics
$3.58 /

-0.125 (-3.37%)

Recommendations
Mustang Bio price target lowered to $6 from $13 at B. Riley » 08:03
01/24/22
01/24
08:03
01/24/22
08:03
MBIO

Mustang Bio

$1.30 /

-0.065 (-4.76%)

B. Riley analyst Mayank…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MBIO Mustang Bio
$1.30 /

-0.065 (-4.76%)

MBIO Mustang Bio
$1.30 /

-0.065 (-4.76%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
MBIO Mustang Bio
$1.30 /

-0.065 (-4.76%)

Recommendations
INmune Bio price target lowered to $20 from $32 at B. Riley » 08:02
01/24/22
01/24
08:02
01/24/22
08:02
INMB

INmune Bio

$8.79 /

-0.08 (-0.90%)

B. Riley analyst Mayank…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
INMB INmune Bio
$8.79 /

-0.08 (-0.90%)

INMB INmune Bio
$8.79 /

-0.08 (-0.90%)

09/07/21 B. Riley
INmune Bio price target raised to $32 from $26 at B. Riley
07/14/21 B. Riley
INmune Bio price target raised to $34 from $29 at B. Riley
04/21/21 B. Riley
B. Riley starts 'under-followed' INmune Bio with Buy, $29 target
04/21/21 B. Riley
INmune Bio initiated with a Buy at B. Riley
INMB INmune Bio
$8.79 /

-0.08 (-0.90%)

INMB INmune Bio
$8.79 /

-0.08 (-0.90%)

Hot Stocks
FedEx, Microsoft announce new cross-platform logistics solution for e-commerce » 08:02
01/24/22
01/24
08:02
01/24/22
08:02
FDX

FedEx

$244.88 /

-6.2 (-2.47%)

, MSFT

Microsoft

$295.81 /

-5.71 (-1.89%)

FedEx (FDX) and Microsoft…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FDX FedEx
$244.88 /

-6.2 (-2.47%)

MSFT Microsoft
$295.81 /

-5.71 (-1.89%)

FDX FedEx
$244.88 /

-6.2 (-2.47%)

01/20/22 BofA
BofA upgrades C.H. Robinson to Buy, seeks values in Transportation
12/29/21 Argus
FedEx price target raised to $285 from $270 at Argus
12/20/21 Credit Suisse
FedEx price target raised to $336 from $330 at Credit Suisse
12/17/21 JPMorgan
FedEx price target raised to $312 from $305 at JPMorgan
MSFT Microsoft
$295.81 /

-5.71 (-1.89%)

07:35 Today Wedbush
Wedbush expects another robust performance from Microsoft in December quarter
01/20/22 Morgan Stanley
Sony named a 'Research Tactical Idea' at Morgan Stanley
01/20/22 BMO Capital
Activision Blizzard price target raised to $95 from $90 at BMO Capital
01/20/22 Citi
Microsoft price target lowered to $376 from $407 at Citi
FDX FedEx
$244.88 /

-6.2 (-2.47%)

MSFT Microsoft
$295.81 /

-5.71 (-1.89%)

FDX FedEx
$244.88 /

-6.2 (-2.47%)

MSFT Microsoft
$295.81 /

-5.71 (-1.89%)

FDX FedEx
$244.88 /

-6.2 (-2.47%)

MSFT Microsoft
$295.81 /

-5.71 (-1.89%)

FDX FedEx
$244.88 /

-6.2 (-2.47%)

MSFT Microsoft
$295.81 /

-5.71 (-1.89%)

Hot Stocks
Lyell Immunopharma announces FDA clearance of IND for LYL132 » 08:02
01/24/22
01/24
08:02
01/24/22
08:02
LYEL

Lyell Immunopharma

$5.24 /

-0.26 (-4.73%)

, GSK

GlaxoSmithKline

$45.09 /

+0.21 (+0.47%)

Lyell Immunopharma (LYEL)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LYEL Lyell Immunopharma
$5.24 /

-0.26 (-4.73%)

GSK GlaxoSmithKline
$45.09 /

+0.21 (+0.47%)

LYEL Lyell Immunopharma
$5.24 /

-0.26 (-4.73%)

07/12/21 JPMorgan
Lyell Immunopharma initiated with an Overweight at JPMorgan
07/12/21 Morgan Stanley
Lyell Immunopharma initiated with an Overweight at Morgan Stanley
07/12/21 BofA
Lyell Immunopharma initiated with a Buy at BofA
07/12/21 Goldman Sachs
Lyell Immunopharma initiated with a Buy at Goldman Sachs
GSK GlaxoSmithKline
$45.09 /

+0.21 (+0.47%)

01/19/22 Societe Generale
Societe Generale double upgrades Unilever after selloff on 'clumsy' bid
01/19/22 Citi
Procter & Gamble unlikely to bid for GSK unit, says Citi
01/17/22 Bernstein
Unilever downgraded to Underperform from Market Perform at Bernstein
01/17/22 Barclays
Unilever downgraded to Equal Weight from Overweight at Barclays
LYEL Lyell Immunopharma
$5.24 /

-0.26 (-4.73%)

GSK GlaxoSmithKline
$45.09 /

+0.21 (+0.47%)

  • 17
    Jun
GSK GlaxoSmithKline
$45.09 /

+0.21 (+0.47%)

GSK GlaxoSmithKline
$45.09 /

+0.21 (+0.47%)

LYEL Lyell Immunopharma
$5.24 /

-0.26 (-4.73%)

GSK GlaxoSmithKline
$45.09 /

+0.21 (+0.47%)

Recommendations
MiNK Therapeutics price target lowered to $10 from $24 at B. Riley » 08:02
01/24/22
01/24
08:02
01/24/22
08:02
INKT

MiNK Therapeutics

$3.11 /

-0.2 (-6.04%)

B. Riley analyst Kalpit…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
INKT MiNK Therapeutics
$3.11 /

-0.2 (-6.04%)

INKT MiNK Therapeutics
$3.11 /

-0.2 (-6.04%)

11/09/21 Evercore ISI
Evercore starts Agenus spinout MiNK Therapeutics with an Outperform
11/09/21 B. Riley
MiNK Therapeutics initiated with Buy, $24 target at B. Riley
11/09/21 William Blair
William Blair starts MiNK at Outperform ahead of 'numerous catalysts'
11/09/21 Baird
Baird starts MiNK Therapeutics at Outperform on iNKT platform potential
  • 15
    Oct
INKT MiNK Therapeutics
$3.11 /

-0.2 (-6.04%)

Recommendations
Infinity Pharmaceuticals price target lowered to $5 from $7 at B. Riley » 08:02
01/24/22
01/24
08:02
01/24/22
08:02
INFI

Infinity Pharmaceuticals

$1.22 /

-0.065 (-5.06%)

B. Riley analyst Kalpit…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
INFI Infinity Pharmaceuticals
$1.22 /

-0.065 (-5.06%)

INFI Infinity Pharmaceuticals
$1.22 /

-0.065 (-5.06%)

12/16/21 B. Riley
Infinity Pharmaceuticals price target raised to $7 from $4 at B. Riley
12/10/21 Piper Sandler
Infinity Pharmaceuticals presents updated Phase II data, says Piper Sandler
10/18/21 H.C. Wainwright
Infinity Pharmaceuticals initiated with a Buy at H.C. Wainwright
08/02/21 JPMorgan
JPMorgan upgrades Infinity Pharmaceuticals on urothelial cancer opportunity
INFI Infinity Pharmaceuticals
$1.22 /

-0.065 (-5.06%)

  • 12
    Feb
INFI Infinity Pharmaceuticals
$1.22 /

-0.065 (-5.06%)

INFI Infinity Pharmaceuticals
$1.22 /

-0.065 (-5.06%)

Recommendations
In8bio price target lowered to $9 from $19 at B. Riley » 08:02
01/24/22
01/24
08:02
01/24/22
08:02
INAB

In8bio

$3.23 /

-0.18 (-5.28%)

B. Riley analyst Kalpit…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
INAB In8bio
$3.23 /

-0.18 (-5.28%)

INAB In8bio
$3.23 /

-0.18 (-5.28%)

08/24/21 Mizuho
In8bio initiated with a Buy at Mizuho
08/23/21 B. Riley
In8bio initiated with a Buy on cancer potential at B. Riley
08/23/21 B. Riley
In8bio initiated with a Buy at B. Riley
  • 30
    Jul
INAB In8bio
$3.23 /

-0.18 (-5.28%)

Recommendations
Heat Biologics price target lowered to $10 from $15 at B. Riley » 08:02
01/24/22
01/24
08:02
01/24/22
08:02
HTBX

Heat Biologics

$2.71 /

-0.12 (-4.24%)

B. Riley analyst Mayank…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HTBX Heat Biologics
$2.71 /

-0.12 (-4.24%)

HTBX Heat Biologics
$2.71 /

-0.12 (-4.24%)

08/25/21 Alliance Global Partners
Heat Biologics price target lowered to $20 from $32 at Alliance Global Partners
08/18/21 B. Riley
Heat Biologics price target lowered to $15 from $20 at B. Riley
05/06/21 Alliance Global Partners
Heat Biologics price target lowered to $32 from $40 at Alliance Global Partners
03/02/21 Cantor Fitzgerald
Heat Biologics initiated with an Overweight at Cantor Fitzgerald
HTBX Heat Biologics
$2.71 /

-0.12 (-4.24%)

Hot Stocks
Ero Copper announces offering of $400M of senior notes due 2030 » 08:02
01/24/22
01/24
08:02
01/24/22
08:02
ERO

Ero Copper

$13.37 /

-0.535 (-3.85%)

Ero Copper is pleased to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ERO Ero Copper
$13.37 /

-0.535 (-3.85%)

ERO Ero Copper
$13.37 /

-0.535 (-3.85%)

01/20/22 Scotiabank
Ero Copper upgraded to Outperform from Sector Perform at Scotiabank
01/12/22 National Bank
Ero Copper price target lowered to C$21 from C$30 at National Bank
01/12/22 BMO Capital
Ero Copper price target lowered to C$29 from C$30 at BMO Capital
01/12/22 Canaccord
Ero Copper price target lowered to C$23.50 from C$25 at Canaccord
Recommendations
GT Biopharma price target lowered to $18 from $26 at B. Riley » 08:01
01/24/22
01/24
08:01
01/24/22
08:01
GTBP

GT Biopharma

$2.65 /

-0.04 (-1.49%)

B. Riley analyst Justin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GTBP GT Biopharma
$2.65 /

-0.04 (-1.49%)

GTBP GT Biopharma
$2.65 /

-0.04 (-1.49%)

06/24/21 B. Riley
GT Biopharma price target raised to $26 from $21 at B. Riley
05/24/21 H.C. Wainwright
GT Biopharma initiated with a Buy at H.C. Wainwright
04/13/21 B. Riley
B. Riley starts GT Biopharma with Buy, sees 101% upside in shares
04/13/21 B. Riley
GT Biopharma initiated with a Buy at B. Riley
GTBP GT Biopharma
$2.65 /

-0.04 (-1.49%)

  • 11
    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.